Moxetumomab pasudotox

Last updated

Moxetumomab pasudotox
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD22
Clinical data
Trade names Lumoxiti
Other namesmoxetumomab pasudotox-tdfk, CAT-8015
AHFS/Drugs.com Monograph
MedlinePlus a618052
License data
Pregnancy
category
  • Contraindicated [1]
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C2804H4339N783O870S14
Molar mass 63388.01 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. [2] [3] [4] Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. [4] The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. [5] This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.

Contents

Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. [4] HCL is named after these extra B cells which look “hairy” when viewed under a microscope. [4] As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced. [4]

Medical uses

Moxetumomab pasudotox as monotherapy is indicated for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA). [2] [3]

Adverse effects

Common side effects include infusion-related reactions, swelling caused by excess fluid in body tissue (edema), nausea, fatigue, headache, fever (pyrexia), constipation, anemia and diarrhea. [2] [3] [4]

The prescribing information for moxetumomab pasudotox includes a boxed warning about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels into surrounding tissues. [2] [4] Symptoms of capillary leak syndrome include difficulty breathing, weight gain, hypotension, or swelling of arms, legs and/or face. [4] The boxed warning also notes the risk of hemolytic uremic syndrome, a condition caused by the abnormal destruction of red blood cells. [2] [4]

Other serious warnings include: decreased renal function, infusion-related reactions and electrolyte abnormalities. [2] [4]

Women who are breastfeeding should not be given moxetumomab pasudotox. [2] [4] [1]

Discovery and ownership background

On 1 November 2005, Cambridge Antibody Technology (CAT) announced it was acquiring two anti-CD22 immunotoxin products from Genencor, namely GCR-3888 and GCR-8015. [6] Genencor is the biotechnology division of Danisco [7] and the acquisition meant CAT would hire certain former Genencor key employees to be responsible for the development of the programmes. [8]

GCR-3888 and GCR-8015 were discovered and initially developed by the National Cancer Institute, which is part of the U.S. National Institutes of Health. Genencor licensed the candidates for hematological malignancies and entered into a Cooperative Research and Development Agreement (CRADA) with the NIH, which will now be continued by CAT. Under the original license agreement with the NIH, CAT gained the rights to a portfolio of intellectual property associated with the programs and would pay future royalties to the NIH.

CAT intended to file an Investigational New Drug (IND) application for GCR-8015 in various CD22 positive B-cell malignancies, including Non-Hodgkin lymphoma and chronic lymphocytic leukemia, following a period of manufacturing development which is expected to be complete by the end of 2006 and to support the NCI's ongoing development of GCR-3888 in Hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (pALL). [6]

CAT-8015 exhibited a greater affinity for CD22 than its predecessor, CAT-3888 [9] and CAT's language such as "CAT will support the NCI's ongoing development of CAT-3888..." suggested at the time that their focus was on the second generation candidate. [10]

CAT was acquired by AstraZeneca, who also acquired MedImmune, combining the two into a biologics division. MedImmune renamed CAT-8015 to moxetumomab pasudotox. [11] [12]

On 16 May 2013, AstraZeneca announced that CAT-8015 had started Phase III clinical trials. [13] [14]

History

On 5 December 2008, orphan designation (EU/3/08/592) was granted by the European Commission to Medimmune Limited, United Kingdom, for murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38 for the treatment of hairy cell leukaemia. [15] It was renamed to Moxetumomab pasudotox. [15] The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019. [15]

On 17 July 2013, orphan designation (EU/3/13/1150) was granted by the European Commission to MedImmune Ltd, United Kingdom, for moxetumomab pasudotox for the treatment of B-lymphoblastic leukaemia / lymphoma. [16] The sponsorship was transferred to AstraZeneca AB, Sweden, in January 2019. [16]

Moxetumomab pasudotox was approved for use in the United States in September 2018. [4]

The efficacy of moxetumomab pasudotox was studied in a single-arm, open-label clinical trial of 80 subjects who had received prior treatment for hairy cell leukemia with at least two systemic therapies, including a purine nucleoside analog. [4] The trial measured durable complete response (CR), defined as maintenance of hematologic remission for more than 180 days after achievement of CR. [4] Thirty percent of subjects in the trial achieved durable CR, and the overall response rate (number of subjects with partial or complete response to therapy) was 75 percent. [4]

The US Food and Drug Administration (FDA) granted the application for moxetumomab pasudotox fast track, priority review, and orphan drug designations. [4] [17] The FDA granted the approval of a Biologics License Application for Lumoxiti to AstraZeneca Pharmaceuticals. [4] This was subsequently transferred to Innate Pharma in March 2020. [18]

On 10 December 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Lumoxiti, intended for the treatment of relapsed or refractory hairy cell leukemia after two prior systemic therapies including a purine nucleoside analog. The orphan designation for Lumoxiti for treatment of hairy cell leukaemia was also maintained. [19] The applicant for this medicinal product is AstraZeneca AB. Moxetumomab pasudotox was approved for medical use in the European Union in February 2021. [3] The EU marketing authorization was withdrawn in July 2021. [3]

Related Research Articles

An immunotoxin is an artificial protein consisting of a targeting portion linked to a toxin. When the protein binds to that cell, it is taken in through endocytosis, and the toxin kills the cell. They are used for the treatment of some kinds of cancer and a few viral infections.

<span class="mw-page-title-main">Hairy cell leukemia</span> Hematological malignancy

Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a subtype of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up about 2% of all leukemias, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe combined.

<span class="mw-page-title-main">Nelarabine</span> Chemical compound

Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

<span class="mw-page-title-main">MedImmune</span> Biopharmaceutical company, acquired by AstraZeneca in 2007

MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.

<span class="mw-page-title-main">Melphalan</span> Chemical compound

Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.

<span class="mw-page-title-main">Cladribine</span> Pharmaceutical drug

Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

<span class="mw-page-title-main">Vandetanib</span> Chemical compound

Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase. The drug was developed by AstraZeneca who later sold the rights to Sanofi in 2015.

<span class="mw-page-title-main">Tremelimumab</span> Monoclonal antibody

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

<span class="mw-page-title-main">Inotuzumab ozogamicin</span> Chemical compound

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

<span class="mw-page-title-main">CD22</span> Lectin molecule

CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.

<span class="mw-page-title-main">Ira Pastan</span> American scientist

Ira Pastan is an American scientist at the National Cancer Institute. He is a member of the National Academy of Sciences, a Fellow of the AAAS and the American Society of Microbiology. In 2009, he was awarded the prestigious International Antonio Feltrinelli Prize for Medicine. His wife, Linda Pastan, was an American poet.

An anti-CD22 immunotoxin is a monoclonal antibody linked to a cytotoxic agent. They are being studied in the treatment of some types of B-cell cancer.

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

<span class="mw-page-title-main">Olaparib</span> Chemical compound (cancer therapy drug)

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

<span class="mw-page-title-main">Cambridge Antibody Technology</span> Defunct British biotechnology company

Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England, United Kingdom. Its core focus was on antibody therapeutics, primarily using Phage Display and Ribosome Display technology.

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.

<span class="mw-page-title-main">Durvalumab</span> Pharmaceutical drug

Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

<span class="mw-page-title-main">Acalabrutinib</span> Chemical compound

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings.

<span class="mw-page-title-main">Duvelisib</span> PI3K inhibitor

Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor.

<span class="mw-page-title-main">Loncastuximab tesirine</span> Medication

Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.

References

  1. 1 2 "Moxetumomab pasudotox (Lumoxiti) Use During Pregnancy". Drugs.com. 22 October 2018. Retrieved 20 April 2020.
  2. 1 2 3 4 5 6 7 8 "Lumoxiti- moxetumomab pasudotox injection, powder, lyophilized, for solution IV solution stabilizer solution". DailyMed. 25 January 2019. Retrieved 20 April 2020.
  3. 1 2 3 4 5 6 "Lumoxiti EPAR". European Medicines Agency (EMA). 9 December 2020. Retrieved 1 May 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 "FDA approves new kind of treatment for hairy cell leukemia". U.S. Food and Drug Administration (FDA) (Press release). 13 September 2018. Retrieved 20 April 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  5. ↑ Kreitman RJ, Pastan I (October 2011). "Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox". Clinical Cancer Research. 17 (20): 6398–405. doi:10.1158/1078-0432.CCR-11-0487. PMC   3201735 . PMID   22003067.
  6. 1 2 "Cambridge Antibody Technology Acquires Oncology Product Candidates from Genencor" (Press release). Cambridge Antibody Technology. Retrieved 12 May 2010.
  7. ↑ "Genencor". Archived from the original on 7 January 2009. Retrieved 12 August 2009.
  8. ↑ "Investor News". Archived from the original on 20 January 2013. Retrieved 17 May 2013.
  9. ↑ "News Releases - National Cancer Institute". Press.nci.nih.gov. Archived from the original on 12 July 2012. Retrieved 12 May 2010.
  10. ↑ "Cambridge Antibody Technology Announces Preliminary Results for the Year Ended 30 September 2005. | Goliath Business News". Goliath.ecnext.com. Archived from the original on 31 October 2021. Retrieved 12 May 2010.
  11. ↑ "USAN Moxetumomab Pasudotox" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association.
  12. ↑ "New Drugs Online Report for moxetumomab pasudotox". Uk Medicines Information. Archived from the original on 3 March 2016. Retrieved 17 May 2013.
  13. ↑ Connolly A (16 May 2013). "AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trials". Bloomberg.
  14. ↑ "AstraZeneca accelerates cancer drug testing". Reuters. 16 May 2013.
  15. 1 2 3 "EU/3/08/592". European Medicines Agency. 5 December 2008. Retrieved 20 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  16. 1 2 "EU/3/13/1150". European Medicines Agency. 17 July 2013. Retrieved 20 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  17. ↑ "Moxetumomab pasudotox-tdfk Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). Retrieved 20 April 2020.
  18. ↑ Gormley N. "Supplemental biologics license application (sBLA) for LUMOXITI (moxetumomab pasudotox-tdfk) for injection" (PDF). Center for Drug Evaluation and Research. Letter to David Lucking (Innate Pharma, Inc.). U.S. Food and Drug Administration.
  19. ↑ "Lumoxiti: Pending EC decision". European Medicines Agency (EMA). 10 December 2020. Retrieved 11 December 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.